Chronic Obstructive Pulmonary Disease | Unmet Need | Severe to Very Severe | US EU | 2025
The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, LABA/LAMA/ICSs, and, most recently, the PDE-3/PDE-4 inhibitor Ohtuvayre and the IL-4/IL-13 inhibitor Dupixent compete in the maintenance drug space. Unfortunately, none of these agents can reverse the progression of COPD or repair lung tissue; instead, current drug treatment focuses on improving breathing and reducing inflammation. Although inhaled medications can reduce the burden of COPD by easing its symptoms, patients’ quality of life still suffers, and the disease remains one of the leading causes of death worldwide. Thus, significant unmet need remains for more-effective or disease-modifying therapies, especially for those patients with more-severe COPD whose symptoms are not adequately controlled with available therapies.
Questions answered
- Which drug attributes most influence pulmonologists’ prescribing decisions for COPD, which have limited impact, and which are hidden opportunities?
- How do current therapies, such as BI’s Spiriva and Stiolto, GSK’s Anoro and Trelegy, AstraZeneca’s Symbicort, Sanofi / Regeneron’s Dupixent, and Verona’s Ohtuvayre perform on these measures?
- What trade-offs across different clinical / nonclinical attributes and price are acceptable to U.S. and European pulmonologists for a hypothetical new COPD drug?
Product description
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Geography: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 30 European pulmonologists
Key drugs covered: Dupixent, Anoro, Spiriva, Symbicort, Trelegy, Ohtuvayre
Key analyses: Importance of clinical and nonclinical product attributes to physicians; Assessment of current drug performance against treatment drivers and goals; Physician perceptions of unmet needs in the indication and related indications; Remaining drug development opportunities
Key feature: Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
